← Back to Knowledge Base

Primary topic: ACADS gene cellular energy production

ACADS Gene and Metabolism: What It Can Mean in a Pathway Report

ACADS is tracked because it connects to fatty-acid oxidation, mitochondrial transport, organic-acid handling, or high-demand energy metabolism. The current evidence index links this gene to Mitochondrial energy with 2 SNPs and 2 curated claims.

What is the ACADS gene?

Short-chain acyl-CoA dehydrogenase enzyme supporting mitochondrial short-chain fatty-acid beta-oxidation.

How ACADS affects metabolism

When ACADS-related function is shifted, the practical effect is interpreted through fatty-acid oxidation, mitochondrial transport, organic-acid handling, or high-demand energy metabolism. This does not mean the pathway is active or impaired right now; it means the gene can help prioritize what to check next.

What happens when ACADS is altered

Altered ACADS signal should be treated as a DNA-based tendency, not a diagnosis. 2 claims currently pass the report-use gate. The useful question is whether symptoms, labs, and lifestyle context line up with the pathway signal.

Curated SNP evidence for ACADS

These SNPs come from the approved study-level evidence model. Each claim is scored from curated study rows, then gated before it can influence pathway scoring.

Mitochondrial energy

Evidence-backed report connection

ACADS currently has 3 curated SNPs, 5 claim-level scores, and 2 claims eligible for pathway scoring.

Open the sample report
rs1799958ACADS Gly209Ser1 claims · 2 study rows

enzyme activity · A

SCAD activity and C4-acylcarnitine tendency

Moderate

rs1799958 A / ACADS Gly209Ser is associated with lower SCAD activity tendency and higher C4-acylcarnitine tendency.

ACADS rs1799958 A is staged as a reduced short-chain acyl-CoA dehydrogenase function allele with acylcarnitine flux support.

Likely effectLower enzyme activity signal
Signal sizeSmall signal
Evidence supportStrong support
Report useIncluded in pathway scoring
Show study evidence
PLOS One 2019 ACADS genotype modelfunctional assay · directThe checked PLOS source names rs1799958G>A / p.G209S and reports genotype-dependent ACADS mRNA/protein decrease with altered acylcarnitine flux in cellular fatty-acid oxidation models.ClinVar VCV000003831clinical curation · close proxyClinVar was checked for rs1799958 / ACADS identity and clinical variant context; it is used as supporting curation rather than primary scoring evidence.
rs1800556ACADS Arg171Trp1 claims · 2 study rows

enzyme activity · T

SCAD activity and C4-acylcarnitine tendency

Moderate

rs1800556 T / ACADS Arg171Trp is associated with lower short-chain acyl-CoA dehydrogenase activity tendency and higher C4-acylcarnitine or ethylmalonic-acid biochemical tendency.

ACADS rs1800556 T is staged as a common reduced-SCAD-function biochemical modifier allele.

Likely effectLower enzyme activity signal
Signal sizeSmall signal
Evidence supportStrong support
Report useIncluded in pathway scoring
Show study evidence
GeneReviews SCADDclinical curation · directThe checked GeneReviews chapter identifies ACADS c.511C>T as one of two common variants that can lead to the SCADD biochemical phenotype and reduce enzymatic activity, while emphasizing absent proven clinical significance.JAMA 2006 SCADD heterogeneity studybiomarker association · directThe checked JAMA study defined SCADD biochemically by repeated elevated C4-carnitine and/or ethylmalonic acid plus ACADS mutation or c.511C>T/c.625G>A variants on both alleles, and tabulated c.511C>T as p.Arg171Trp.
rs20143553 claims · 6 study rows

biomarker tendency · CC

ACADS-linked insulin-release biomarker tendency

Not used for pathway scoring

rs2014355 CC is associated with reduced ACADS-linked insulin-release biomarker tendency.

ACADS rs2014355 is scored as a cautious glucose-stimulated insulin-release biomarker tendency for C-containing genotypes, based on population OGTT association evidence.

Likely effectLower biomarker tendency
Signal sizeSmall signal
Evidence supportModerate support
Report useEvidence only, not scored
Show study evidence
NCBI RefSNP recordidentity only · unknownNCBI RefSNP data identify rs2014355 as an intronic ACADS variant with T and C alleles. This supports the simplified TT, CT, and CC genotype labels used in this record.PMC3022800biomarker association · directHornbak et al. reported that the minor C allele of rs2014355 in ACADS was associated with reduced measures of glucose-stimulated insulin release during an oral glucose tolerance test in glucose-tolerant Danish individuals, including lower 30-minute insulin and lower incremental insulin AUC. This supports a reduced insulin-release biomarker tendency for C-containing genotypes.

biomarker tendency · CT

ACADS-linked insulin-release biomarker tendency

Not used for pathway scoring

rs2014355 CT is associated with reduced ACADS-linked insulin-release biomarker tendency.

ACADS rs2014355 is scored as a cautious glucose-stimulated insulin-release biomarker tendency for C-containing genotypes, based on population OGTT association evidence.

Likely effectLower biomarker tendency
Signal sizeSmall signal
Evidence supportModerate support
Report useEvidence only, not scored
Show study evidence
NCBI RefSNP recordidentity only · unknownNCBI RefSNP data identify rs2014355 as an intronic ACADS variant with T and C alleles. This supports the simplified TT, CT, and CC genotype labels used in this record.PMC3022800biomarker association · directHornbak et al. reported that the minor C allele of rs2014355 in ACADS was associated with reduced measures of glucose-stimulated insulin release during an oral glucose tolerance test in glucose-tolerant Danish individuals, including lower 30-minute insulin and lower incremental insulin AUC. This supports a reduced insulin-release biomarker tendency for C-containing genotypes.

biomarker tendency · TT

ACADS-linked insulin-release biomarker tendency

Not used for pathway scoring

rs2014355 TT has no scored directional claim for ACADS-linked insulin-release biomarker tendency.

ACADS rs2014355 is scored as a cautious glucose-stimulated insulin-release biomarker tendency for C-containing genotypes, based on population OGTT association evidence.

Likely effectNo clear biomarker tendency
Signal sizeMinimal signal
Evidence supportVery limited support
Report useEvidence only, not scored
Show study evidence
NCBI RefSNP recordidentity only · unknownNCBI RefSNP data identify rs2014355 as an intronic ACADS variant with T and C alleles. This supports the simplified TT, CT, and CC genotype labels used in this record.PMC3022800biomarker association · directHornbak et al. reported that the minor C allele of rs2014355 in ACADS was associated with reduced measures of glucose-stimulated insulin release during an oral glucose tolerance test in glucose-tolerant Danish individuals. This supports C-containing genotype scoring, while TT is kept neutral for the exact claim.

Common symptoms people report

  • low energy under fasting, illness, or exercise
  • slow recovery after exertion
  • fatigue that feels out of proportion to workload

Biomarkers to validate

CBC, ferritin, and thyroid context

Rules out common non-DNA explanations for low energy.

Glucose and HbA1c

Checks whether fuel handling is adding pressure.

Organic acids or acylcarnitines when available

Adds more specific mitochondrial and fatty-acid oxidation context.

Where DNA analysis helps

DNA helps decide whether ACADS deserves attention inside the broader Mitochondrial energy pathway. It is most useful when combined with biomarkers instead of used as a standalone answer.

Example interpretation

ACADS may add context to fatty-acid oxidation, mitochondrial transport, organic-acid handling, or high-demand energy metabolism, especially when its SNP evidence lines up with other genes in the same pathway.

Suggested validation: CBC, ferritin, and thyroid context.

What to do next

  • Review the Mitochondrial energy pathway result before interpreting ACADS on its own.
  • Use relevant biomarkers to confirm whether this DNA tendency is visible in current biology.
  • Treat supplement or nutrition decisions as follow-up steps only after the pattern fits symptoms or labs.

Upload your DNA file and receive a structured metabolic pathway analysis with prioritized insights and suggested validation markers.

Get My DNA Report

Related pages

PPARGC1A

PPARGC1A gene DNA analysis

UCP2

UCP2 gene DNA analysis

Fasting insulin

fasting insulin and metabolism

GSH/GSSG ratio

GSH GSSG ratio explained

Mitochondrial energy and recovery pathway

mitochondrial energy recovery pathway

Caffeine and stimulant sensitivity pathway

caffeine stimulant sensitivity pathway

How accurate are DNA metabolism reports?

how accurate are DNA metabolism reports

Genetic test for weight loss Europe

genetic test for weight loss Europe

Related symptom angle

Low energy metabolism causes

Browse the knowledge base

See the full index of gene guides, biomarker guides, pathway guides, symptoms, buyer pages, and common questions.